Clinical overview of the synucleinopathies
- PMID: 14502652
- DOI: 10.1002/mds.10559
Clinical overview of the synucleinopathies
Abstract
The term synucleinopathies is used to name a group of neurodegenerative disorders characterized by fibrillary aggregates of alpha-synuclein protein in the cytoplasm of selective populations of neurons and glia. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atrophy (MSA). Clinically, they are characterized by a chronic and progressive decline in motor, cognitive, behavioural, and autonomic functions, depending on the distribution of the lesions. Because of clinical overlap, differential diagnosis is sometimes very difficult. Parkinsonism is the predominant symptom of PD, but it can be indistinguishable from the parkinsonism of DLB and MSA. Autonomic dysfunction, which is an isolated finding in PAF, may be present in PD and DLB, but is usually more prominent and appears earlier in MSA. DLB could be the same disease as PD but with widespread cortical pathological states, leading to dementia, fluctuating cognition, and the characteristic visual hallucinations. The deposition of aggregates of synuclein in neurons and glia suggests that a common pathogenic mechanism may exist for these disorders. Even though synuclein may play an important role in disease development in these disorders, in light of the different symptom complex and prognosis and management issues that characterize each disorder, we think that the term synucleinopathy has little practical value as a diagnostic term for the clinician. Clinicians should attempt to reach standard clinical diagnosis on patients, such as PD, PAF, or MSA.
Copyright 2003 Movement Disorder Society
Similar articles
-
Neuropathological spectrum of synucleinopathies.Mov Disord. 2003 Sep;18 Suppl 6:S2-12. doi: 10.1002/mds.10557. Mov Disord. 2003. PMID: 14502650 Review.
-
[Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].Rinsho Shinkeigaku. 1999 Dec;39(12):1285-6. Rinsho Shinkeigaku. 1999. PMID: 10791099 Japanese.
-
alpha-Synuclein is phosphorylated in synucleinopathy lesions.Nat Cell Biol. 2002 Feb;4(2):160-4. doi: 10.1038/ncb748. Nat Cell Biol. 2002. PMID: 11813001
-
Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.J Neurol. 2003 Oct;250 Suppl 3:III11-4. doi: 10.1007/s00415-003-1303-x. J Neurol. 2003. PMID: 14579119
-
[Alpha-synucleinopathies].Neurologia. 2001 Apr;16(4):163-70. Neurologia. 2001. PMID: 11412709 Review. Spanish.
Cited by
-
Heat shock proteins: cellular and molecular mechanisms in the central nervous system.Prog Neurobiol. 2010 Oct;92(2):184-211. doi: 10.1016/j.pneurobio.2010.05.002. Epub 2010 Jun 4. Prog Neurobiol. 2010. PMID: 20685377 Free PMC article. Review.
-
Small Heat Shock Proteins, Big Impact on Protein Aggregation in Neurodegenerative Disease.Front Pharmacol. 2019 Sep 18;10:1047. doi: 10.3389/fphar.2019.01047. eCollection 2019. Front Pharmacol. 2019. PMID: 31619995 Free PMC article. Review.
-
Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.J Neuroimmune Pharmacol. 2019 Sep;14(3):423-435. doi: 10.1007/s11481-019-09835-4. Epub 2019 Jan 31. J Neuroimmune Pharmacol. 2019. PMID: 30706414 Free PMC article.
-
Autonomic dysfunctions in parkinsonian disorders.J Mov Disord. 2009 Oct;2(2):72-7. doi: 10.14802/jmd.09019. Epub 2009 Oct 30. J Mov Disord. 2009. PMID: 24868361 Free PMC article.
-
A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.PLoS One. 2013;8(2):e55848. doi: 10.1371/journal.pone.0055848. Epub 2013 Feb 5. PLoS One. 2013. PMID: 23393603 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous